Climb Bio Website
1 known investors
Climb Bio develops monoclonal antibody therapies for immune-mediated diseases, advancing clinical-stage candidates such as budoprutug for conditions including immune thrombocytopenia. Its investigational therapies target patients with limited treatment options.